Ascentia Biomedical Corporation Announces New Laboratory and Office Space; Adds Dr. Peter Klein, Renown Pharmaceutical Chemist t
July 25 2005 - 9:25AM
PR Newswire (US)
Ascentia Biomedical Corporation Announces New Laboratory and Office
Space; Adds Dr. Peter Klein, Renown Pharmaceutical Chemist to Its
Staff BELLEVUE, Wash., July 25 /PRNewswire-FirstCall/ -- Ascentia
Biomedical Corporation (OTC Pink Sheets: ASCE), a leading
researcher and developer of efficacious pharmaceuticals, compounds
and other products, announces the lease of office and laboratory
space in West Park Business Center in Redmond, WA. Dr. James
Clagett, President and CEO of Ascentia said, "We are pleased to
have a new facility that is in excess of 6,000 square feet of
office and laboratory space with ample room for expansion. This new
complex offers improved facilities, which will house our future
state-of-the-art laboratory and equipment to afford us the ability
to get our in-house research and development programs underway.
Importantly, it will permit Ascentia to increase its capacity for
pre-clinical contract research, which brings added revenue to
support operations. It will provide our outstanding team of
researchers an environment in which to excel." Ascentia has also
added a new member to its on-staff scientific team. Dr. Peter Klein
joins Ascentia Biomedical to oversee its chemistry division where
he will spearhead the Company's efforts in the development of
anti-tumor and anti-inflammatory therapeutics. In addition, Dr.
Klein will bring added opportunities for generation of revenues by
increasing the scope of pre- clinical contract research services
provided to clients. He has 13 years of pharmaceutical R&D
experience including 8 years directing the discovery chemistry
program at Cell Therapeutics where he led projects in the discovery
and development of oncology and immunology therapeutics and drug
delivery systems. He also has served as a consultant for the
pharmaceutical industry including the discovery of agents to treat
central nervous system disorders. Dr. Klein began his career as a
research investigator with the Department of Medicinal Chemistry at
the University of Washington following a Ph.D. in synthetic organic
chemistry and a B.Sc. in chemistry and cell biology both from the
University of Washington. He holds 44 issued pharmaceutical
patents. About Ascentia Biomedical Corporation Our focus is
SOLUTIONS through RESEARCH and DISCOVERY. Ascentia is developing
and commercializing new pharmaceutical and biomedical products for
application in a number of areas, including treatment for asthma,
arthritis, psoriasis and cancer. Initially, a majority of these
products will be secured through direct purchase or through
licensing. As the Company grows and evolves, more products will be
developed internally. Ascentia is focused on therapies for cancer
and diseases of inflammation. For more information visit the
Company's website at: http://www.ascentiabiomedical.com/ Certain
statements contained herein are "forward looking" statements as
such term is defined in the Private Securities Litigation Reform
Act of 1995. Because statements include risks and uncertainties,
actual results may differ materially from those expressed or
implied and include, but are not limited to, those discussed in
filings by the Company with the Securities and Exchange Commission.
DATASOURCE: Ascentia Biomedical Corporation CONTACT: Dr. James
Clagett, President & CEO of Ascentia Biomedical Corporation,
+1-425-462-5686; or Jim Drewitz, Investor Relations,
+1-972-355-6070, for Ascentia Biomedical Corporation Web site:
http://www.ascentiabiomedical.com/
Copyright